The global Cell and Gene Therapy (CGT) Pharmaceuticals market size is predicted to grow from US$ 18030 million in 2025 to US$ 52790 million in 2031; it is expected to grow at a CAGR of 19.6% from 2025 to 2031.

Cell and Gene Therapy (CGT) drugs are a class of innovative treatments that treat diseases by changing the patient's cells or genes. Specifically, CGT drugs usually include: 1. Gene therapy: by introducing, deleting or repairing genes into the patient's cells, the purpose is to correct diseases caused by genetic defects or mutations. For example, gene therapy can deliver normal genes to patients through viral vectors to replace missing or defective genes.

2. Cell therapy: by changing or enhancing the patient's own cells and then re-injecting them into the body for treatment. Common cell therapies include using immune cells (such as CAR-T cells) to treat cancer or using stem cells to repair damaged tissues.

United States market for Cell and Gene Therapy (CGT) Pharmaceuticals is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Cell and Gene Therapy (CGT) Pharmaceuticals is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Cell and Gene Therapy (CGT) Pharmaceuticals is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Cell and Gene Therapy (CGT) Pharmaceuticals players cover Vericel, Castle Creek, Terumo, Nipro, BioCardia, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Cell and Gene Therapy (CGT) Pharmaceuticals Industry Forecast” looks at past sales and reviews total world Cell and Gene Therapy (CGT) Pharmaceuticals sales in 2024, providing a comprehensive analysis by region and market sector of projected Cell and Gene Therapy (CGT) Pharmaceuticals sales for 2025 through 2031. With Cell and Gene Therapy (CGT) Pharmaceuticals sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cell and Gene Therapy (CGT) Pharmaceuticals industry.

This Insight Report provides a comprehensive analysis of the global Cell and Gene Therapy (CGT) Pharmaceuticals landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Cell and Gene Therapy (CGT) Pharmaceuticals portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Cell and Gene Therapy (CGT) Pharmaceuticals market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cell and Gene Therapy (CGT) Pharmaceuticals and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cell and Gene Therapy (CGT) Pharmaceuticals.

This report presents a comprehensive overview, market shares, and growth opportunities of Cell and Gene Therapy (CGT) Pharmaceuticals market by product type, application, key players and key regions and countries.

Segmentation by Type:

    Cell Therapy Drugs
    Gene Therapy Drugs

Segmentation by Application:

    Hospital
    Clinic
    Other

This report also splits the market by region:

    Americas

        United States
        Canada
        Mexico
        Brazil

    APAC

        China
        Japan
        Korea
        Southeast Asia
        India
        Australia

    Europe

        Germany
        France
        UK
        Italy
        Russia

    Middle East & Africa

        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

    Vericel
    Castle Creek
    Terumo
    Nipro
    BioCardia
    Sanpower Group
    Novartis
    Gilead Sciences, Inc./Fosun Kite
    BMS
    JW (Cayman) Therapeutics
    Legend Biotech Corp./Johnson & Johnson
    Innovent Biologics, Inc./IASO Biotherapeutics
    Juventas/CASI
    CARsgen Therapeutics Holdings
    Huadong Medicine
    inno.N
    lovance
    Mesoblast
    Takeda
    Pierre fabre
    Aurion Biotech
    Gamida Cell
    CellTrans
    SiBiono Gene Technology
    Ferring
    Kyowa Kirin
    uniQure
    Roche
    PTC Therapeutics
    BioMarin
    CSL
    Sarepta
    AnGes
    bluebird bio
    Krystal Biotech